Sign In
Buy ETNB
$14.84
+0 (+0%)
At Close: Jan 29, 2026
89bio, Inc. (ETNB) Presents At Citi's Biopharma Back To School Conference Transcript
03:05pm, Wednesday, 03'rd Sep 2025
89bio, Inc. (NASDAQ:ETNB ) Citi's Biopharma Back to School Conference September 3, 2025 11:15 AM EDT Company Participants Rohan Palekar - CEO & Director Conference Call Participants Geoffrey Meacham -
89bio to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 28'th Aug 2025
SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the
89bio: Promising As Pegozafermin Nears Phase 3 Readout
08:22am, Monday, 11'th Aug 2025
Pegozafermin is ETNB's long-acting FGF21 analog. It's undergoing three Phase 3 trials. Two of those late-stage trials are for MASH (F2-F4), and the third is for severe hypertriglyceridemia. Also, ETNB
89bio (ETNB) Q2 R&D Jumps 131%
10:38pm, Thursday, 07'th Aug 2025
89bio (ETNB) Q2 R&D Jumps 131%
89bio Reports Second Quarter 2025 Financial Results and Corporate Updates
04:05pm, Thursday, 07'th Aug 2025
– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 topline histology data expected in 1H 2027 and in 2028, respectively; each trial designed to support accelerated approval to treat patients with
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 04'th Aug 2025
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercializat
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 09'th Jul 2025
SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercializat
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 06'th Jun 2025
SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercializat
89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference
04:05pm, Wednesday, 04'th Jun 2025
SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercializat
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 09'th May 2025
SAN FRANCISCO, May 09, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercializati
89bio to Participate in Upcoming Investor Conferences
04:05pm, Tuesday, 06'th May 2025
SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercializati
89bio Reports First Quarter 2025 Financial Results and Corporate Updates
04:05pm, Thursday, 01'st May 2025
– Topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 1H 2027 and in 2028, respectively; each trial is designed to support accelerated approval to t
89bio: A Buy With Strong Market Opportunity In MASH And SHTG
04:46am, Friday, 18'th Apr 2025
Initiate Buy rating for 89bio, Inc. due to promising lead candidate pegozafermin targeting MASH and SHTG with encouraging Phase 2 data. Pegozafermin may have faster fibrosis improvement and better saf
Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year?
10:40am, Thursday, 06'th Mar 2025
Here is how 89BIO (ETNB) and Eton Pharmaceuticals, Inc. (ETON) have performed compared to their sector so far this year.
89bio to Participate in the Leerink Partners Global Healthcare Conference
04:05pm, Monday, 03'rd Mar 2025
SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercializa
